Work & Life

Menopause in Black Women

Creator: Dr Nadira Awal
Published: 2026-01-15

Longer, hotter, and often less well supported — what the SWAN data teaches UK care.

By Dr Nadira AwalBMS Specialist3 min readMedically reviewed 9 July 2026

Warm-toned botanical arrangement in soft window light

The SWAN cohort shows Black women often experience longer, more intense vasomotor symptoms. Equal access to evidence-based HRT and specialist care is a health-equity issue.

The SWAN cohort — the largest longitudinal study of menopause across ethnicities — shows Black women experience vasomotor symptoms (hot flushes and night sweats) that are more frequent, more severe and last on average 10+ years, compared to around 7 in the whole cohort. Despite that, Black women are consistently less likely to be offered HRT, more likely to have symptoms attributed to stress or hypertension, and more likely to reach menopause without a proper review. As a women's health GP and BMS specialist I see the gap closing — but it is still there, and it matters.

What SWAN and UK data show

Vasomotor symptoms last a median of 10.1 years in Black women vs 6.5 years in Japanese-American women and 7.4 years overall.
Symptoms are more severe on validated scoring tools (MRS, Greene Climacteric Scale).
Menopause occurs slightly earlier on average — around age 49.
Cardiovascular disease and hypertension present earlier and are more likely to be undertreated.
Fibroids and heavy menstrual bleeding are 2–3 times more common — often untreated for years before menopause.

Access and equity — closing the gap

Black women in the UK are prescribed HRT at lower rates than white women even after adjusting for age and comorbidities.
Symptoms are more often attributed to hypertension, stress or 'lifestyle' — not menopause.
The full range of body-identical HRT preparations should be offered on merit, not filtered by unstated assumptions.
Testosterone should be considered where symptoms fit — libido, energy and mood — not withheld on cultural grounds.
Specialist review is worth arranging early when symptoms are severe or long-lasting.

Cardiovascular and metabolic protection

Blood pressure monitored at least annually from age 40, more often if borderline or on treatment.
HbA1c or fasting glucose regularly — insulin resistance often develops silently in perimenopause.
Cholesterol panel and QRISK3 review by age 40 and repeated every 3–5 years.
Transdermal (patch, gel, spray) HRT is preferred where there is any cardiovascular concern — it avoids first-pass liver effects.
Discuss lifestyle factors specifically — sleep, alcohol, salt, movement — without moralising.

Fibroids, heavy bleeding and hysterectomy

Investigate any heavy or irregular bleeding — ultrasound, full blood count, ferritin — do not accept 'that's just your periods'.
Mirena IUS is highly effective for heavy bleeding and provides endometrial protection if HRT is added later.
Uterine artery embolisation and myomectomy are alternatives to hysterectomy in many cases.
After hysterectomy without oophorectomy, ovarian function may still decline earlier — perimenopausal symptoms still count.

Bone, skin and hair

Osteoporosis risk is lower on average but not absent — assess individually, especially with steroid use, early menopause or family history.
Vitamin D deficiency is common — check level and replace if below 50 nmol/L.
Menopausal skin changes and hair thinning (androgenetic and traction patterns) benefit from a proper dermatology or trichology review.
Hyperpigmentation and melasma can worsen — sunscreen and gentle topical retinoids help.

Community resources and peer support

The Black Menopause Collective — advocacy, community and evidence-based information.
Nyah Health Programme — Black women's health and menopause support.
Local peer groups — often the fastest route into confident conversation with clinicians.
Menopause Mandate and The Menopause Charity — general resources that increasingly reflect diverse experience.

Key takeaway

Longer, harder symptoms deserve fuller, faster care. Black women should be offered the same evidence-based menopause options as everyone else — and offered them earlier.

How Dr Awal approaches this in clinic

Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.

A detailed 60 minute first appointment — no rushed 10-minute slots.
Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
Body-identical HRT considered first-line where appropriate.
Shared-care letters sent to your NHS GP so treatment can continue affordably.
Follow-up at 3 months to fine-tune your regimen and address side effects.
Ongoing annual reviews so your plan evolves with you.

Common questions we hear about this

Do I need to be at a certain age to be seen?

No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.

Will my GP continue the prescription?

In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.

What if I've tried HRT before and it didn't suit me?

Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.

How long will I need to stay on treatment?

There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.

Where do you see patients?

All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.

About the author

Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.

Sources & further reading

General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.

Talk it through